Detalhe da pesquisa
1.
Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
N Engl J Med
; 369(9): 819-29, 2013 Aug 29.
Artigo
Inglês
| MEDLINE | ID: mdl-23984729
2.
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
Lancet
; 383(9911): 60-68, 2014 Jan 04.
Artigo
Inglês
| MEDLINE | ID: mdl-24094767
3.
Quantification of oxalate by novel LC-MS/MS: assay development, validation and application in lumasiran clinical trials.
Bioanalysis
; 15(9): 481-491, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-37195004
4.
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation.
Clin Pharmacokinet
; 62(10): 1509-1522, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37639169
5.
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection.
Drugs R D
; 21(4): 455-465, 2021 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-34741731
6.
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
Clin Pharmacol Ther
; 110(5): 1250-1260, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34510420
7.
Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.
Clin Pharmacokinet
; 60(3): 365-378, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33047216
8.
Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects.
Clin Pharmacol Ther
; 109(2): 372-382, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32599652
9.
Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.
Clin Pharmacol Ther
; 108(1): 63-72, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31994716
10.
Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
J Clin Pharmacol
; 60(1): 37-49, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31322739
11.
Correction to: Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.
Clin Pharmacokinet
; 61(6): 919, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-35579826
12.
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
Cancer Discov
; 3(4): 406-17, 2013 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-23358650
13.
Biochemical characterization of the first essential two-component signal transduction system from Staphylococcus aureus and Streptococcus pneumoniae.
J Mol Microbiol Biotechnol
; 5(4): 252-60, 2003.
Artigo
Inglês
| MEDLINE | ID: mdl-12867749